Neurelis, Inc.

Rare and pediatric disease drug sponsors and the US Food and Drug Administration could resolve several ongoing rare and pediatric drug development issues in a compromise bill to fund the government th

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

Legal challenges of US Food and Drug Administration exclusivity determinations are among the early cases where the Supreme Court’s overturning of the Chevron doctrine of deference is being cited. Th

All of the six novel agents with April 2024 user fee goal dates at the US FDA are using an expedited review pathway, the Pink Sheet FDA Performance Tracker’s User Fee Goal Dates tracker shows: fou